HSANZ Council

Dr Adam Bryant

Adam Bryant is a Senior Staff Specialist at Liverpool Hospital where he has worked since 2012 as a development member of the allogeneic BMT program which commenced at this time. Adam’s other specific subspecialty interest is as a core member of the Liverpool Hospital Myeloma Subspecialty Unit. Adam and his colleagues are responsible for an exceptionally large practice of myeloma patients. This unit has been a strong recruiter for many Phase 2 and 3 clinical studies of myeloma therapies. Adam has been the Principle Investigator of several myeloma trials and is an active member of the Australia Leukaemia and Lymphoma Group Myeloma Working Party.
His major other role is as Chair of the rapidly expanding Haematology Clinical Trials Unit of South Western Sydney that aims to bring new and innovative therapies to the patients of this previously underserviced region. Adam has also had various roles with the NSW Cancer Institute, in particular as the Chair of the EviQ Haematology Reference Committee.

A/Prof Andrea Henden

A/Prof Andrea Henden (BSc MBBS (Hons) FRACP FRCPA PhD) is a clinical Haematologist and Bone Marrow Transplant physician at the Royal Brisbane and Women's Hospital in Brisbane, Australia and a holder of a Metro North Clinician Research Fellowship. She has a clinical interest in transplantation and cellular therapies, and the infectious complications of these treatments. A/Prof Henden is also a research officer in the Translational Cancer Immunotherapy Laboratory at QIMR Berghofer Medical Research Institute. Her research focusses on transplant immunology and current active projects include cellular therapies for infection, and the role of the microbiome and metabolism on T cell function in the context of transplantation and cellular therapy. She is the Principal Investigator on a number of Investigator Initiated Clinical Trials bringing novel immunotherapies to the clinic, with a focus toward treating complications of immunotherapies.  

Dr Sumita Ratnasingam

Dr Sumi Ratnasingam (AdvDipMedSci, BMedSci, MBBS, FRACP, FRCPA, GCertCncrSc) is a clinical haematologist at The Alfred Hospital, specialising in lymphoma and CAR-T cell therapy. She also practices at Epworth HealthCare, balancing the demands of public and private practice.
Sumi spent more than a decade at University Hospital Geelong, providing comprehensive haematology care across the Barwon region and Bellarine Peninsula. This experience reinforced her commitment to ensuring regional patients have equitable access to world-class therapies. During this time, she also served as a senior lecturer at Deakin University and held several leadership roles within the hospital.
Her work extends beyond clinical care, with active involvement in research and clinical trials. She has been a principal investigator on multiple national and international lymphoma studies and regularly contributes to publications through the Australasian Lymphoma Alliance (ALA) and Australasian Leukaemia & Lymphoma Group (ALLG). She is currently Medical Secretary for the ALLG Lymphoma Scientific Working Party.
Dedicated to education and governance, Sumi mentors future physicians and haematologists, serves on the Committee for Joint College Training (CJCT), and the Central Appointments Process for Haematology Advanced Training (CAPHAT), as a HSANZ representative.
Sumi remains committed to advancing innovative therapies and improving outcomes for patients with blood cancers through her clinical practice, research, and advocacy.

Dr Nicole Wong Doo

Dr Nicole Wong Doo (MBBS (Hons), PhD, FRACP, FRCPA, GradCert[ClinTch]) is a clinical and laboratory haematologist at Concord Repatriation General Hospital, senior lecturer at Concord Clinical School and Honorary Research Associate at the Cancer Council Victoria. As the Director of the Haematology Clinical Research Unit at Concord Hospital, she leads a team of 25 in the delivery of clinical trials embedded within clinical practice and clinical-translational research. Since completing a PhD in lymphoma and myeloma epigenetics at the University of Melbourne, she has built a growing portfolio of clinical research, as the Australian principal investigator of the ALLG HD13 RADAR trial in hodgkin lymphoma supported by the MRFF. She has ongoing research interests in lymphoma and multiple myeloma clinical trials and supportive care, including being a member of the ALLG Multiple Myeloma, Lymphoma and Supportive Care Scientific Working Parties, member of the Australasian Lymphoma Alliance and on the Steering Committee of the Australasian Myeloma Research Consortium. With a growing profile in patient-reported outcomes (PRO) research, she leads a PRO study in Oral therapy for Blood Diseases and is PI of a digital research project called MyHodgkin MyHealth, a mobile App for patient-entered health outcomes in Hodgkin lymphoma. Dr Wong Doo is dedicated to promoting excellence in Haematology in the Asia-Pacific region and works to deliver training and education as a member of the Royal College of Pathologists Australasia Pathology Education Outreach Committee (PEOC).

Dr James Liang

Currently clinical and laboratory haematologist at Middlemore Hospital. After completing his medical degrees (BHBm MBChB) in 2005 from the University of Auckland, James continued his medical training in the Auckland region. In 2015 he was awarded a research fellowship from Cancer and Palliative Network (Perth, Australia) and spent 2016-2017 at the University of Western Australia and Sir Charles Gairdner Hospital. Since that time, he maintains special interest in adult haematological cancer especially in myeloproliferative neoplasm.

A/Prof Cindy Lee

Associate Professor Cindy Lee trained as a haematologist in Perth, then further her studies in the UK on a clinical fellowship awarded by the European Group for Blood and Marrow Transplantation (EBMT). There, she studied immunotherapies and targeted radiotherapy in Myeloma. On return to Australia in 2009, she was appointed as a clinical and laboratory haematologist at the Royal Adelaide and Queen Elizabeth Hospitals.

Cindy treats all blood disorders and has particular expertise in blood cancers (such as lymphoma and leukaemias), with a particular clinical focus on Myeloma and Amyloidosis. She has particular research interest in the use of targeted therapies, immunotherapies and stem cell transplantation. Her leadership is recognised by Medical and Scientific Advisory Group (MSAG) for Myeloma Australia and the Centre for International Blood and Marrow Transplant Registry CIBMTR). She co-ordinates haematology teaching for the Adelaide Medical School

Cindy is well known for her passion and dedication to her patients, to enable them to feel empowered about their conditions and be able to make informed decisions about their health. Cindy is happy to consult in English and Mandarin.

Outside of work, Cindy enjoys cooking and spending time with her 2 children.

Dr Andrew Guirguis

Dr Andrew Guirguis is a Clinical Haematologist at Austin Health and a Clinical Lab Head at the Olivia Newton-John Cancer Research Institute in Melbourne, Victoria since 2024. His clinical and research interests focus on understanding and targeting drivers of pre-leukaemic myeloid neoplasms, including the myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and myeloproliferative neoplasms (MPN). A University of Melbourne graduate, Andrew holds dual fellowships with the Royal Australasian College of Physicians (RACP) and the Royal College of Pathologists of Australasia (RCPA). He completed haematology training at the Alfred Hospital and a PhD at the Australian Centre for Blood Diseases, earning the HSANZ Baikie Medal. His postdoctoral research includes fellowships under Professor Ben Ebert at the Dana-Farber Cancer Institute and Professor Mark Dawson at the Peter MacCallum Cancer Centre. Andrew serves on the Acute Leukaemia and Laboratory Science Working Parties within the Australasian Leukaemia and Lymphoma Group (ALLG). Outside of work, he enjoys traveling, long-distance running and playing the piano – though he admits the latter two are still works in progress.

Dr Prudence (Pru) Smith

Pru Smith is a haematologist at Hobart Hospital.

Dr Matthew (Matt) Wright

Matt Wright is a clinical and lab Haematologist from Fiona Stanley Hospital in Perth.
He completed training in Sydney before enjoying a transplant fellowship in Vancouver, and later a sabbatical in Cambridge focussed on MPN.
His clinical interests are myeloid neoplasms and allotransplant, and he is a passionate teacher of laboratory medicine. Matt is a national examiner for the RCPA and RACP, and enjoys travelling to teach in the Asia-pacific region.
In his spare time Matt likes ocean swimming and losing to his two boys at Golf.

Stephanie Anderson

Stephanie Anderson is the Early Career representative for HSANZ.  She is currently undertaking a PhD titled ‘Gene editing to cure Sickle Cell Disease’ at the Australian Centre for Blood Diseases and is a recipient of the HSANZ New Investigator Scholarship. Stephanie undertook a Bachelor of Medical Science before graduating from medicine at the University of Sydney. She has dual Fellowship of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia. Stephanie is an avid hockey player, and enjoys taking her dog for walks along St Kilda beach.

Ty Simpson

Ty Simpson is a pioneering Haematology Nurse Practitioner at The Alfred, leading Australia’s CAR-T cell therapy program and transforming cancer care.

He's known for his compassionate leadership, national impact on nursing education, and dedication to improving patient outcomes - especially in complex clinical trials. Ty was named 2025 Australian Nurse of the Year. 

Ty also leads a nurse-led network across Australia and New Zealand, upskilling regional teams and ensuring expert care continues beyond hospital walls. His work is reshaping how nurses lead, learn, and deliver cutting-edge treatment.

Dr Jackie Yim

Dr Jackie Yim is a healthcare leader with a PhD in Health Economics and over a decade of experience spanning clinical practice, research, and operations. His career has focused on advancing patient outcomes, driving innovation, and improving healthcare systems—particularly in oncology. He has held roles overseeing multidisciplinary teams, leading research initiatives, and developing programs that strengthen both patient care and clinical research. Jackie is also a Visiting Fellow at the Centre for Health Economics Research and Evaluation (CHERE) at the University of Technology Sydney. With a unique blend of clinical, research, and operational expertise, Jackie excels at integrating insights across these domains to deliver sustainable, evidence-based solutions to complex healthcare challenges. He is nearing completion of his MBA and the AICD Company Directors Course, and looks forward to supporting the HSANZ Council in advancing the haematology profession through strong governance and strategic leadership.